Dr. Papa on CAR T-Cell Therapy for Head and Neck Cancer

Video

Sophie Papa, PhD, MBBS, MRCP, King’s College London in the United Kingdom, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with head and neck cancer.

Sophie Papa, PhD, MBBS, MRCP, King’s College London in the United Kingdom, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with head and neck cancer.

CAR T-cell therapy has become a standard of care for patients with hematologic cancers, explains Papa. It is now attempting to be used for patients with head and neck cancer. Head and neck cancer is a solid tumor that poses many challenges to CAR T-cell therapy.

In this patient population, T cells are administered intratumorally as opposed to intravenously to target the main activity in the local regional disease and reduce the risk of the T cells getting into the circulation therefore lowering the risk of toxicities, states Papa.

Related Videos
Kari Wisinski, MD, Endowed Professor of Hematology and Oncology, chief, Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health; associate director, Clinical Research, co-lead, Breast Cancer Disease Oriented Team, UW Carbone Cancer Center
Susan C. Modesitt, MD, FACOG, FACS, professor, Department of Gynecology and Obstetrics, director, Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine
Nikhil A. Gopal, MD
Hans C. Lee, MD
Manish A. Shah, MD
Jobelle Baldonado, MD
Alexey Danilov, MD, PhD,
Alexey Danilov, MD, PhD
Hayder Saeed, MD
Robert Huddart, PhD, leader, Clinical Academic Radiotherapy Team, The Institute of Cancer Research; professor, urological cancer, honorary consultant, Urological Oncology, The Royal Marsden NHS Foundation Trust